Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU

Regulatory Policy

2 articles

Ho Chi Minh City mandates 100% electric ride-hailing fleets by 2030, outpacing EU targets

Ho Chi Minh City mandates 100% electric ride-hailing fleets by 2030, outpacing EU targets

Ho Chi Minh City will require all ride-hailing platforms to operate exclusively electric vehicle fleets by January 2030. The mandate applies to services like Grab and Be, forcing a complete phase-out of combustion engine vehicles. Vietnam's approach contrasts sharply with the EU's market-based incentives and later timelines for transport electrification.

ViaNews Editorial Team (Europe)•
US Consumer Finance Watchdog Faces Abolition Risk as EU Weighs Regulatory Model

US Consumer Finance Watchdog Faces Abolition Risk as EU Weighs Regulatory Model

The US Consumer Financial Protection Bureau confronts a 70% probability of political shutdown or severe operational cuts. The agency monitors credit card fees and overdraft charges across American financial products. European regulators are watching closely as the outcome could reshape global consumer protection frameworks.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com